 Bloomberg | Novartis posts sharp drop in 1st-qtr profit; challenges UK off-label Avastin use The Pharma Letter Afinitor (everolimus), an oral inhibitor of the mTOR pathway used across multiple diseases, made a strong contribution to pharmaceuticals growth in the first quarter with sales of $143 million (+60% cc). Everolimus was submitted to regulatory agencies ... Novartis first-quarter profit down 8% |
